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Summary
Object. — The French Cardiology Society (SFC) systematically recommends (Class I) transesophageal
echocardiography (TEE) after any mitral valve replacement with a mechanical prosthesis (MMVR).
Taking into account the increasing workload of echocardiography laboratories, our attitude was to
propose that only post-operative transthoracic echocardiography (TTE) is performed. The purpose
of this study was to evaluate the possible risks of this simplified procedure. 
Methods. — We performed a precise analysis of one full year of practice of MMVR with
exhaustive follow-up for the first 2 years concentrating on thromboembolic complications. 
Results. — From January to December 2003, 84 MMVRs (46 after rheumatic fever, 22 degenerative
disease, 11 infective endocarditis (IE) and 5 ischemia) were conducted in 45 women and 39 men
of average age 61 years. Early mortality (< 30 days) concerned 5 patients (5.9%). A control TTE
to determine normal prosthetic function was performed 7±2 days after surgery and this revealed
2 cases of nonobstructive thrombosis which were treated medically, 3 cases of paraprosthetic
regurgitation, and 1 vegetation due to underlying IE. Actuarial survival was 90.5% at 1 year and
83.3% at 2 years. After a mean follow-up of 179.3 patient-years, 5 patients were reoperated
(5.9%): 1 for IE, 1 for paravalvular regurgitation, 1 for mitral valve insufficiency with haemolysis,
and 2 for obstructive prosthetic valve thromboses. In addition there were 2 cases of prosthetic
valve thrombosis, 8 ischemic strokes (2 ministrokes, 6 sequelar strokes), and 1 peripheral
embolism. The global thromboembolic complication rate was therefore 6.1 per 100 patient-years
(n=11). There were 4 hemorrhagic events, i.e. a rate of 2.2 events per 100 patient-years. 63% of
the 1193 INR conducted were within the target range (3-4.5), 26% were below 3 and 11% were
greater than 4.5. 35 % of patients with thromboembolic complications had an INR < 3.
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Conclusion. — Morbidity and mortality during the first 2 years after MMVR were relatively high
but equivalent to the values of comparable series in the literature. These complications would
not have been reduced by a more precise screening based on early TEE. Despite the increasingly
litigious nature of the doctor-patient relationship, it would probably be excessive to oppose
that this guideline was not followed in a dispute; in particular as it is difficult to apply this
measure as echocardiography departments are overworked.
© 2008 Published by Elsevier Masson SAS.
Résumé
Objet : La Société Française de Cardiologie (SFC) recommande (classe I) la réalisation d’une
échocardiographie trans-œsophagienne (ETO) systématiquement au décours de tout
remplacement valvulaire mitral par prothèse mécanique (RVMM). Compte tenu de la surcharge
croissante des laboratoires d’échocardiographie, notre attitude est de se contenter
uniquement d’une échocardiographie trans-thoracique (ETT) postopératoire et il nous est
apparu nécessaire d’évaluer les éventuels risques liés à cette procédure simplifiée.
Méthodes : Nous avons étudié précisément une année complète d’exercice de RVMM avec un
suivi exhaustif de 2 ans se concentrant sur les complications thromboemboliques.
Résultats : De janvier à décembre 2003, 84 RVM mécaniques (46 après rhumatisme articulaire, 22
dystrophies, 11 endocardites infectieuses (EI), 5 ischémiques) ont été réalisés chez 45 femmes et
39 hommes d’âge moyen 61 ans. La mortalité précoce (< 30 jours) concernait 5 patients (5,9 %). A
7 ± 2 jours postopératoires, les patients bénéficiaient d’une ETT de contrôle du bon
fonctionnement prothétique, ETT qui révélait 2 thromboses non obstructives traitées
médicalement, 3 fuites para prothétiques, et 1 végétation dans un contexte d’EI. La survie
actuarielle était de 90,5 % à 1 an et de 83,3 % à 2 ans. Avec un recul moyen de 179,3 patient-
années, 5 patients (5,9 %) ont été réopérés : 1 pour EI, 1 pour fuite para valvulaire, 1 pour
insuffisance mitrale avec hémolyse, et 2 pour thromboses de prothèses obstructives. On notait en
plus de ces 2 thromboses de prothèse, 8 AVC ischémiques (2 accidents ischémiques transitoires, 6
accidents séquellaires), et 1 embolie périphérique. Le taux global de complications
thromboemboliques était donc de 6,1 pour 100 patient-années (n = 11). On notait 4 événements
hémorragiques, soit un taux de 2,2 événements pour 100 patient-années. Sur les 1193 INR réalisés,
63 % étaient dans la cible (3-4,5), 26 % étaient inférieurs à 3 et 11 % étaient supérieurs à 4,5. Chez
les patients ayant connu des complications thromboemboliques, on notait 35 % d’INR < 3.
Conclusion : La morbi-mortalité après RVMM au cours des 2 premières années est relativement
lourde mais équivalente à celle des séries comparables de la littérature. Surtout ces
complications n’étaient pas susceptibles d’être diminuées par un dépistage plus précis basé sur
une ETO précoce. Compte tenu d’une judiciarisation croissante de la relation médecin-patient,
cette recommandation potentiellement opposable en cas de litige pourrait s’avérer excessive
et ce d’autant que les disponibilités habituelles des laboratoires d’échographie rend cette
mesure difficilement applicable.
© 2008 Published by Elsevier Masson SAS.
Object
The French Society of Cardiology (SFC) recommends [1]
that transesophageal echocardiography (TEE) is systemati-
cally conducted during the first 3 months after mechanical
mitral valve replacement (MMVR) (class 1 guideline: appen-
dix 1). This recommendation is based on the capacity of TEE
to detect nonobstructive thrombosis (NOT) and strands,
small structures considered to be thrombogenic, as well as
slight physiological or paraprosthetic regurgitation. On the
contrary, the ACC/AHA and ESC recommend TTE [2, 3].
These guidelines are different, but echocardiography has a
different purpose. For Americans and Europeans, TTE is not
performed to detect these potentially thrombogenic
strands, but rather to demonstrate the usefulness of sur-
gery and be used as a reference for follow-up (LVEF, trans-
prosthetic pressure gradient).
Moreover this SFC guideline is not respected, as confirmed
by the survey that we carried out among French cardiac sur-
gery departments. For mainly practical reasons and taking
into account the increasing work overload of echocardiogra-
phy laboratories, our attitude is to propose only post-opera-
tive TTE. We therefore considered it necessary to evaluate
the possible risks related to this simplified procedure.
Methods
We focused our study on one year of practice, from January
to December 2003 during which 84 consecutive MMVRs were
performed with an exhaustive follow-up over 2 years. We
collected for all patients the results of postoperative echo-
cardiography and complications with special attention to
the study of thromboembolic events.
This study is based on the analysis of our computer data-
bases and all patient records were consulted. A comple-
mentary survey by contacting primary care doctors and
patients by post and telephone was performed to obtain a
complete and exhaustive determination of outcomes and
the quality of the anticoagulant treatment by respecting
guidelines on reporting heart valve diseases [4].
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Concerning the anticoagulation protocol, 10,000 IU/24h
of heparin was infused IV post-operatively with an electric
syringe and the dosage was then adjusted from H6 in order
to obtain an APTT from 2 to 3 times the control value in the
absence of blood in the chest tubes (infusion rate < 2mL/
kg/h). An early switch from heparin IV to fluindione was
made on the evening after removal of the chest tubes:
20 mg of fluindione on D1, 15 mg on D2, control by PT-INR
from D2 then every day until discharge from the hospital
with a target INR of 3 to 4.5 in agreement with the current
2003 guidelines [5]. Only patients with associated bypasses
received aspirin 100 mg/24h in addition to VKA.
All the patients underwent TTE to control good prosthe-
tic function within 7±2 days of MMVR surgery before their
discharge from hospital. When the postoperative TTE pros-
thetic evaluations were considered to be normal, patients
were discharged, with TTE scheduled at 6 months and one
year after surgery. An assessment by TEE was only made in
the event of complications.
The differences in the baseline data between groups
were compared with a “t” test for continuous variables and
2 test for categorical variables. Continuous variables were
reported with the mean ±1 standard deviation and catego-
rical variables as a percentage. Linearised rates were used
to describe multiple events and were expressed in events
per 100 patient-years. Independent factors associated with
mortality and thromboembolic events were identified by
log regression and the Cox proportional hazards model. The
data used for calculations are given in the appendices.
These calculations were made with SPSS software.
Results
Post-operative period
From January 1st to December 31st, 2003, 84 MMVRs (46 for
rheumatic fever, 22 for degenerative disease, 11 for infec-
tive endocarditis and 5 for ischemia) were performed in
45 women and 39 men of average age 61.01±12.02 years
[26; 82]. These comprised 46 cases of mitral regurgitation
(MR), 22 with mitral stenosis (MS) and 16 with both MR + MS.
Concomitant diagnoses included 18 cases of aortic regurgi-
tation, 2 of aortic stenosis, 4 of tricuspid regurgitation, 1 of
tricuspid stenosis and 3 atrial septal defects. 44 patients
(51.7%) had atrial fibrillation (AF) with a history of from
2 months to 39 years (mean value 6.8 years). 
The surgery performed comprised 84 MMVRs associated
with 19 aortic valve replacements, 9 tricuspid valve annulo-
plasties, 1 tricuspid valve replacement, 8 aortocoronary
bypasses (mean of 1.5 bypass), 3 closures of atrial septum
defect, 1 thrombectomy of LA, 18 ablations of the AF site
(14 by ultrasound, 4 by radiofrequency ablation).
The prostheses implanted (mean diameter 28.74mm; 1 of
23, 10 of 25, 21 of 27, 31 of 29, 11 of 31, 11 of 33 mm) were
all mechanical bileaflet prostheses. The approach was via
median sternotomy in 77 cases, and right minithoracotomy in
7 cases. The mean cardio-pulmonary bypass (CPB) time was
89.39 min and the mean aortic clamping time was 66.56 min.
Mortality at 30 days (table 1) concerned 5 patients (5.9%)
including 2 cases of post-cardiotomy cardiogenic shock, 2 of
septic shock, and 1 acute ventricular arrhythmia (VA). The
mean post-operative LVEF was 57.77±10.87% [30; 78] versus
58.78±9.42% [45; 76] before surgery (table 1). 
The 6 abnormalities diagnosed on the postoperative TTE
were: 2 nonobstructive thromboses (NOT >5 mm) treated
medically by prolongation of IV heparin treatment until
disappearance of the images (and resolution in these
2 patients without complications), 3 minor paraprosthetic
mitral regurgitations with a favourable outcome as the
patients remaining asymptomatic during the first 2 years
studied, and 1 vegetation in a patient with IE requiring repeat
surgery. Complementary assessment by TEE with possible
repeated TEE for monitoring was performed in the 6 patients
with an abnormal post-operative TTE.
Secondary outcome
Actuarial survival (figure 1) was 90.5% at 1 year (8 deaths) and
83.3% at 2 years (6 deaths). The 2-year mortality of men 20.5%
(n=8) was higher than that of women 13.3% (n=6). (NS)
(figure 1). Causes of death included 10 deaths of cardiac ori-
gin: 4 due to post-cardiotomy cardiogenic shock, 3 to ischemic
heart disease, 1 to acute VA, 1 dilated cardiomyopathy (DCM),
and 1 IE on the prosthesis i.e. only 1 death related to the
valve. The other causes of death were 2 septic shocks, 1 acute
respiratory distress syndrome (ARDS), 1 end-stage chronic
renal failure, and 1 bronchial carcinoma. Secondary mortality
was high when the initial diagnosis was IE or ischemia (26.7%
and 20% respectively). None of these deaths could have been
prevented by conducting TEE instead of TTE (table 4).
Mortality was not closely linked to any post-operative
ultrasound parameters (table 2). The following values were
found to be significantly different between dying and survi-
ving patients: a lower LA surface area (figure 2) of 28.7±4.3
cm2 versus 34.5±10.9 cm2 (p=0.026), and a higher systolic
PAP (figure 3) 46±11mmHg versus 36±8mmHg (p=0.036).
This difference in LA area was probably the result of a
higher mortality when the MMVR was carried out for an
acute mitral disease than for a chronic disease. The fol-
lowing factors were found to be associated with mortality
by multivariate analysis (table 3): systolic PAP, LVOT VTI,
clamping and CPB times, aortic diameter, and higher pro-
portion of APTT<2N (figures 2, 3).
100
Percent survival (%)
94.0 90.5 90.5 88.1 83.3
24181261
Patients at risk
79 76 76 74 70
Months after Operation
n=84
80
60
40
20
0
Figure 1. Actuarial survival curve.
 Survival Time Standard 
Error 
95% Confidence 
Interval
Mean 26.25 0.42 (25.43; 27.07)
Median 27.00 0.77 (25.50; 28.50)
TTE or TEE after mechanical MVR 207
The 26 patients at high risk (age >75 years, ischemic
disease with LVEF<45%, infective endocarditis) had a higher
mortality than the others (n=58) of 26.9% (7/26) versus
13.8% (8/58), p=0.02.
Thromboembolic complications
During the first week before the conduct of TTE, 1 minis-
troke was observed on D1 and 1 ischemia of the limb on D3
requiring embolectomy. After the first week and after
conducting post-operative TTE, 7 embolic events were noted
(6 strokes and 1 ministroke). All these complications led to
an additional assessment by TTE followed by TEE which
unmasked 4 abnormalities (abnormalities diagnosed on the
2 examinations): 2 medically treated NOT, 1 paraprosthetic
regurgitation, and 1 thrombosis of the mitral prosthesis
requiring repeat MMVR.
We observed overall during the first 2 years after sur-
gery:.2 cases of prosthetic valve thrombosis in patients recei-
ving insufficient anticoagulation (after gynaecological
surgery and subdural haematoma);
Table 1 Prognosis factors of TTE data on survival. Group statistics.
 Number Mean Standard 
Deviation
SEM
LVEF (%) Living 62 58.44 10.791 1.370
 Deceased 9 53.22 10.883 3.628
sPAP (mmHg) (p=0.036) Living 56 36.2321 8.36658 1.11803
 Deceased 9 45.6667 11.09054 3.69685
Mitral surface area (cm2) Living 28 2.9343 1.02662 .19401
 Deceased 5 3.1600 .51284 .22935
Mitral pressure gradient (mmHg) Living 67 5.1881 2.24037 .27370
 Deceased 12 5.8333 3.40009 .98152
LA Dimension (mm) Living 58 46.3621 9.17796 1.20513
 Deceased 10 51.0000 12.38278 3.91578
LA Area (cm2) (p=0.026) Living 38 34.4737 10.91920 1.77133
 Deceased 7 28.7143 4.34796 1.64337
RV-RA Grad (mmHg) Living 45 30.4444 8.00726 1.19365
 Deceased 5 33.0000 6.85565 3.06594
Max Ao Grad (mmHg) Living 29 14.9655 9.43202 1.75148
 Deceased 2 12.5000 12.02082 8.50000
LVOT VTI (cm.s-1) (p=0.06) Living 59 20.2780 4.89951 .63786
 Deceased 10 16.7100 5.05711 1.59920
Shortening Fraction (%) Living 51 36.1098 8.02768 1.12410
 Deceased 8 38.8750 8.69216 3.07314
Clamping Time (min) Living 66 63.6212 30.33493 3.73397
 Deceased 13 75.4615 30.62846 8.49481
CPB Time (min) Living 66 80.9545 29.81504 3.66998
 Deceased 15 117.9333 62.02012 16.01353
End-Diast LV Diam (mm) Living 64 49.6563 8.20418 1.02552
 Deceased 10 52.4000 9.44222 2.98589
End-Syst LV Diam (mm) Living 58 32.8103 8.70664 1.14324
 Deceased 7 37.8571 11.65373 4.40470
Septal Thickness (mm) Living 60 10.4967 1.98144 .25580
 Deceased 8 11.0000 2.39046 .84515
ED LV thickness (mm) Living 61 10.3082 2.09653 .26843
 Deceased 9 10.4444 1.81046 .60349
Ao Diameter (mm) Living 58 31.4914 4.74849 .62351
 Deceased 9 34.8889 6.17342 2.05781
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.9 embolic events (8 strokes and 1 peripheral embolism). 
The total thromboembolic event rate (n=11) was therefore
6.1 per 100 patient-years and 2.2 events for 100 patient-years
for embolic strokes. Among these 11 thromboembolic compli-
cations no risk factor was identified by univariate analysis
(table 4). Multivariate analysis (table 3), identified the fol-
lowing factors associated with the occurrence of thromboem-
bolic events: prosthetic mitral valve area, A wave velocity,
end-diastolic thickness of LV wall and septum, and diameter
of the aorta.
Concerning follow-up of APTT, there was no difference
between the post-operative APTT in the 2 groups: 32.2%
APTT<2N (n=112), 54% 2N<APTT<3N (n=188), and 13.8%
APTT>3N (n=48) in victims versus 31.4% APTT<2N (n=485),
50.3% 2N<TCA<3N (n=778), and 18.3% APTT>3N (n=283) in
unaffected patients.
On the contrary during follow-up, an INR<3 was more fre-
quently observed in the group with thromboembolic com-
plications: 35.3% versus 26.2% for all patients (35.3% INR<3
(n=42), 58% 3<INR<4.5 (n=69), and 6.7% INR>4.5 (n=8), ver-
sus 26.1% INR<3 (n=312), 62.9% 3<INR<4.5 (n=750), and
11.0% INR>4.5 (n=62)).
Haemorrhagic complications
4 major haemorrhagic accidents were observed with hospi-
talization: 2 cases of anaemia requiring transfusion, one
post-surgical haematoma and one subdural haematoma i.e.
a haemorrhagic complication rate of 2.2 per 100 patient-
years.
Secondary surgery
Further surgery with repeat MMVR (2 during first year) was
carried out for the five following reasons: severe parapros-
thetic regurgitation, haemolysis due to paraprosthetic
regurgitation, recurrent IE on the prosthesis and 2 cases of
thrombosis with unsatisfactory anticoagulation (hysterec-
tomy and subdural haematoma). 
Table 2 Multivariate analysis of factors associated with
mortality and the occurrence of thromboembolic events.
Correlation matrix (extract).
  Living and 
deceased
Thrombo-
embolic
Significance Living and deceased  .248
 thromboembolic .248  
 Ejection fraction .122 .476
 sPAP .005 .423
 Mitral area .326 .030
 Mitral gradient .216 .412
 LA Dimension .100 .148
 LA area .100 .184
 RV/RA GRAD .296 .352
 LVOT VTI .028 .198
 Max Ao Grad .409 .093
 Mean Ao Grad .199 .156
 Shortening Frac-
tion
.212 .367
 Clamping time .109 .354
 CPB Time .000 .237
 Days in ICU .000 .498
 APTT < 2N .026 .179
 INR < 3 .188 .295
 E wave .445 .157
 A wave .395 .014
 E/A ratio .331 .110
 ED LV Diameter .196 .488
 ES LV Diameter .132 .458
 Septal Thickness .290 .016
 ED LV wall .436 .021
 Diameter Ao .047 .039
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Figure 2. Scatter diagram LA area=f ((LA dimension)2). Discre-
pant data were observed between the mean LA dimension and LA
area with a higher mean LA dimension in deceased patients than in
living patients: 51 mm versus 46 mm whereas the LA area was signi-
ficantly lower in deceased than in living patients: 28.7cm2 versus
34.5cm2. Maybe, this result reflects the wider scatter around the
mean of LA dimensions between acute and chronic mitral valve
diseases, associated with the variability of the ultrasound examina-
tion and operator.
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Table 3 Prognosis factors of TTE data on thromboembolic complications. Group statistics.
 Thromboembolic 
events
n Mean Standard 
Deviation
SEM
LVEF (%) Victims 8 59.13 10.816 3.824
 Event-free 63 57.60 10.946 1.379
sPAP (mmHg) Victims 6 36.0000 4.04969 1.65328
 Event-free 59 37.6949 9.67267 1.25927
Mitral surface area (cm2) Victims 3 3.4667 .90738 .52387
 Event-free 30 2.9187 .96952 .17701
Mitral gradient (mmHg) Victims 9 4.5333 2.25222 .75074
 Event-free 70 5.3829 2.45640 .29360
LA Dimension (mm) Victims 8 42.7500 6.13538 2.16918
 Event-free 60 47.6167 10.02893 1.29473
LA Area (cm2) Victims 4 28.5000 9.88264 4.94132
 Event-free 41 34.0732 10.38602 1.62202
Mean Ao Gradient (mmHg) (p=0.024) Victims 2 5.0000 1.41421 1.00000
 Event-free 31 10.2742 5.29754 .95147
LVOT VTI (cm.s-1) Victims 10 18.3000 4.29599 1.35851
 Event-free 59 20.0085 5.15328 .67090
End-Diastolic LV Diameter (mm) Victims 10 50.4000 7.35149 2.32475
 Event-free 64 49.9688 8.56343 1.07043
Septal Thickness (mm) Victims 10 9.8000 2.14994 .67987
 Event-free 58 10.6862 1.98737 .26095
End-diastolic LV wall thickness (mm) Victims 10 9.2000 2.65832 .84063
 Event-free 60 10.5133 1.89428 .24455
Ao Diameter (mm) Victims 10 28.9000 6.26188 1.98018
 Event-free 57 32.4825 4.66366 .61772
Table 4 History of deaths.
Sex: Cause of Death Etiology of Valve disease Age (yrs) Date death / operation (months)
1 M Cardiogenic shock IE 68.1 M1
2 F Cardiogenic shock Degenerative disease 68.5 M1
3 M Septic shock Rheumatic fever 62.7 M1
4 M Acute VA Degenerative disease 82.5 M1
5 M Septic shock IE 37.0 M1
6 F Cardiogenic shock Degenerative disease 74.5 M3
7 F ARDS Rheumatic fever 73.7 M3
8 F Cardiogenic shock Rheumatic fever 72.7 M5
9 M End-stage renal failure IE 57.4 M14
10 F Ischemic heart disease Ischemia 72.4 M14
11 F. Ischemic heart disease Ischemia 69.9 M21
12 M Ischemic heart disease Ischemia 53.6 M22
13 M IE on prosthesis IE 64.2 M23
14 M Bronchial carcinoma Degenerative disease 79.1 M24
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Discussion 
Although TEE has a higher sensitivity and specificity for the
evaluation of potential post-surgical prosthetic dysfunc-
tions, the current recommendations of the SFC are too
theoretical and incompatible with currently overworked
echocardiography laboratories. Moreover, they are not
often complied with and all heart surgery centres that we
consulted do not systematically conduct TEE during the
post-operative period. In parallel the ESC and ACC/AHA
recommend that only TTE is performed after mechanical
MVR surgery (grade I guideline), and TEE is only used when
TTE is unsatisfactory or if there is suspected prosthetic dys-
function or infective endocarditis [2, 3]. Moreover, these
more pragmatic recommendations represent economies in
both financial and human terms. 
The series that we report here backs up this less systema-
tic use of TEE with indications restricted to insufficiencies of
TTE and to complications. This series is a review of one year
of practice including 84 consecutive mitral valve replace-
ments with bileaflet mechanical prostheses and exhaustive
follow-up for 2 years with a similar thromboembolic event
rate to that in other published series, varying from 0.8 to
4.6% patient-years [6-20]. A prospective study in 2007
showed a mean thromboembolic event rate of 1.9% patient-
years for Carbomedics prostheses and 1.5 for Saint Jude
prostheses after 10 years of follow-up [21]. The linearised
complication rate in our series may seem higher than the
literature data with a longer follow-up. However, we stu-
died the first 2 years when the embolic risk is significantly
higher [22, 23]. A Canadian study [24] in 2004 on 586 MMVRs
with post-operative TTE gave 2.3 events per 100 patient-
years of sequelar post-embolic stroke, comparable with our
rate (2.2 events for 100 patient-years).
Our series reported 4 major haemorrhagic accidents with
hospitalisation, i.e. 2.2 events per 100 patient-years. Here
too, this rate is comparable to that of other studies in the
literature which report an incidence of haemorrhagic
events of from 1.4 to 2.8 per 100 patient-years [6-
20,24,25]. It should be specified that since 2003, our target
INR has been revised downwards in agreement with the
most recent guidelines (INR of 2.5 to 3.5) [2].
The Rennes study of Laurent [26] sought to evaluate the
value of the heparin-VKA combination in the treatment of
early post-MMVR non-obstructive thrombosis in which a TEE
was systematically practiced post-operatively on D7. This
prospective study concerning 114 patients with 120 MMVRs,
reported 3 obstructive thromboses leading to 1 repeat
MMVR, 26 NOT>5mm (23%) and 5 NOT<5 mm (4.4%). In the
Bordeaux study by Laplace [27] on 680 cases with TEE on D9
after MMVR, 2 obstructive thromboses were observed and
62 NOT (9.4%) with significantly more early and late throm-
boembolic complications in patients with NOT>5mm versus
NOT<5mm. The outcome of these 62 NOT over 34±22
months included 3 ministrokes and 5 strokes, i.e. 4.6 neuro-
logical events per 100 patient-years. It is therefore proba-
ble that our evaluation by simple post-operative TTE unde-
restimates this complication since we detected by TTE only
2.5% of NOT>5mm versus 21.7% and 9.4% in the 2 series
mentioned above using TEE. This data seems to argue in
support of systematic TEE which is undoubtedly the most
sensitive investigation to detect possible thromboembolic
complications, and therefore makes it possible to identify
patients at risk and optimize medical treatment where
necessary. However, we did not find any clinical benefit in
our study, despite the numerous false negatives. Indeed, at
1 year Laurent reported 3 strokes and 2 mini-strokes, i.e.
5 embolic events for 114 patients (4.39%) which is globally
similar to our 4 embolic events for 80 patients (5%). The
possible failure to detect NOT<5mm did not therefore seem
to negatively affect the clinical outcome of patients by an
increased number of events. Moreover, the only 2 prosthe-
tic valve thromboses in our series both occurred as a result
of an inadequate change in anticoagulation, and were the-
refore independent of possible screening by early TEE.
Lastly, none of the deaths in our series could have been
prevented by carrying out a TEE.
Defenders of post-operative TEE stress that the detection
of NOT by TEE (not seen by TTE) as shown by Guéret [28]
results in an optimisation of medical treatment, or even
more aggressive treatment. Various treatments were eva-
luated in the treatment of these early NOT with similar suc-
cess rates: prolonged combination of UFH and VKA [26],
combination of aspirin and VKA, VKA alone [29], with plate-
let aggregation inhibitors such as Abciximab [30], and if
necessary redo surgery or even thrombolysis in the event of
a contraindication to surgery [31].
Rather than screening by TEE, the importance of preven-
tion should be underlined with optimisation of the quality
of peri-operative anticoagulation, as pointed out by Lung
who on 129 TEE performed post-operatively on D15 after
MMVR noted a prevalence of strands in 43% of patients with
the occurrence of early thromboembolic events signifi-
cantly linked to the presence of these strands by TEE.
Moreover, it is the presence of these strands that justifies
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Figure 3. Scatter diagram sPAP=f(RV/RAgrad). There were higher
systolic pulmonary artery pressures in the deceased patient group
than in the living group: 45.67 ± 11.09 mmHg versus 36.23 ± 8.37
mmHg, whereas the RV/RA pressure gradient was not significantly
different: 30.4 mmHg in deceased patients versus 33 mmHg in
living patients. This may be due the low level of RA pressures due
to post CPB hypovolemia, associated with the existence of parado-
xical septal motion after CPB.
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early and optimal post-operative anticoagulation despite
the haemorrhagic risk [32, 33].
Conclusion
Our study confirms that the rate of NOT < 5mm is unde-
restimated when TEE is not systematically performed
after MMVR surgery. However this fact has no effect on
the incidence of thromboembolic complications. We the-
refore consider that the more pragmatic guidelines of
the ACC/AHA and ESC that recommend TTE alone with
complementary TEE only in the event of complications
are sufficient. Lastly, from a medical-legal point of view
this SFC recommendation should not be opposable in case
of a dispute.
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SFC Guidelines. Consensus on the indications for transe-
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luation (first 3 months) of normal valvular prostheses
Class I
— Assessment after mitral valvular replacement by a 
mechanical prosthesis: test for paraprosthetic regurgita-
tion, detection of non-obstructive thrombi and/or 
strands, identification of physiological regurgitation.
— Assessment during atrial rhythm disorders that may be 
regulated in patients not or poorly anti-coagulated.
Class II
— Assessment after mitral valve replacement by a biolo-
gical prosthesis: detection of paraprosthetic regurgita-
tion, nonobstructive thrombi and/or strands, 
identification of physiological regurgitation.
— Assessment after aortic valvular replacement associa-
ted with surgery of the ascending aorta or for infective 
endocarditis.
— Assessment during atrial rhythm disorders that may be 
regulated in a well anti-coagulated patient.
Class III
— Assessment after aortic valvular replacement when 
transthoracic Doppler echocardiography is normal.
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